Literature DB >> 9371330

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

R Hajdu1, R Thompson, J G Sundelof, B A Pelak, F A Bouffard, J F Dropinski, H Kropp.   

Abstract

MK-0991 (L-743,872) is a potent antifungal agent featuring long half-life pharmacokinetics. The pharmacokinetics of MK-0991 administered intravenously to mice, rats, rhesus monkeys, and chimpanzees is presented. Unique to MK-0991 is its consistent cross-species performance. The range of values for the pharmacokinetic parameters were as follows: clearance, 0.26 to 0.51 ml/min/kg; half-life, 5.2 to 7.6 h; and distributive volume, 0.11 to 0.27 liters/kg. The level of protein binding of MK-0991 was determined to be 96% in mouse and human serum. The compound exhibited high affinities for human serum albumin and at least two lipid components. The rationale for the selection of MK-0991 as a drug development candidate was based on its two- to threefold superior pharmacokinetic performance in chimpanzees over the performance of an otherwise equivalent analog, L-733,560. Once-daily dosing for MK-0991 is indicated by a graphical comparison of levels in the circulations of chimpanzees and mice. In a study of the pharmacokinetics of MK-0991 in mouse tissue, the organs were assayed following intraperitoneal administration. The area under the concentration-versus-time curves (AUC) segregated the tissues into three exposure categories relative to plasma. The tissues with greater exposure than that for plasma were liver (16 times), kidney (3 times), and large intestine (2 times). The exposure for small intestine, lung, and spleen were equivalent to that for plasma. Organs with lower levels of exposure were the heart (0.3 times that for plasma), thigh (0.2 times), and brain (0.06 times). Kinetically, drug was cleared more slowly from all tissues than from plasma, indicating that terminal-phase equilibrium had not been achieved by 24 h. Thus, some measure of accumulation is predicted for all tissues. Single daily doses of MK-0991 should provide adequate systemic levels of fungicidal activity as a result of its long half-life pharmacokinetics, wide distribution, and slowly accumulating concentrations in tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371330      PMCID: PMC164125     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases.

Authors:  T J Walsh; J W Lee; E Roilides; P Francis; J Bacher; C A Lyman; P A Pizzo
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

2.  Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.

Authors:  J W Lee; P Kelly; J Lecciones; D Coleman; R Gordee; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP).

Authors:  J M Balkovec; R M Black; M L Hammond; J V Heck; R A Zambias; G Abruzzo; K Bartizal; H Kropp; C Trainor; R E Schwartz
Journal:  J Med Chem       Date:  1992-01       Impact factor: 7.446

4.  Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

Authors:  M S Rouse; B M Tallan; J M Steckelberg; N K Henry; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

7.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Pharmacokinetics of L-671,329 in rhesus monkeys and DBA/2 mice.

Authors:  J G Sundelof; R Hajdu; W J Cleare; J Onishi; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 9.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

10.  Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.

Authors:  R K Brazzell; Y H Park; C B Wooldridge; B McCue; R Barker; R Couch; B York
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

View more
  52 in total

1.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Efficacy of caspofungin against Aspergillus terreus.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Alfredo Santinelli; Annette W Fothergill; Stefania Fallani; Esther Manso; Eleonora Pisa; Daniele Giannini; Andrea Novelli; Maria I Cassetta; Teresita Mazzei; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Serum differentially alters the antifungal properties of echinocandin drugs.

Authors:  Padmaja Paderu; Guillermo Garcia-Effron; Sergey Balashov; Guillaume Delmas; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

4.  Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Authors:  Cristina Jiménez-Ortigosa; Padmaja Paderu; Mary R Motyl; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

5.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

7.  Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Authors:  Emilia Cantón; Javier Pemán; Macrina Sastre; Mónica Romero; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

8.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

9.  Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Authors:  Arnold Louie; Mark Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 10.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.